Enzyme infusion aimed at taming sepsis enters first human safety trial

NCT ID NCT05453695

Recruiting now Disease control Sponsor: McMaster University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether an intravenous enzyme called DNase I is safe and feasible for ICU patients with sepsis. Sepsis is a life-threatening response to infection that can damage organs. The study will enroll 36 adults and monitor how many complete the treatment and blood collection as planned. It is a first step to see if this approach is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DNase I (an enzyme given intravenously)
What this could lead to: If safe and feasible, this could pave the way for a new treatment to reduce organ damage in sepsis.
What could go wrong: This is a very early phase 1 trial with only 36 patients, focused on safety, not effectiveness. It may not show benefit or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRITICAL ILLNESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRITICAL ILLNESS SEPSIS

Contacts and locations

Locations

Hamilton Health Sciences
RECRUITING

Hamilton, Ontario, L8L 0A4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.